[go: up one dir, main page]

AR032398A1 - Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion - Google Patents

Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion

Info

Publication number
AR032398A1
AR032398A1 ARP020100149A ARP020100149A AR032398A1 AR 032398 A1 AR032398 A1 AR 032398A1 AR P020100149 A ARP020100149 A AR P020100149A AR P020100149 A ARP020100149 A AR P020100149A AR 032398 A1 AR032398 A1 AR 032398A1
Authority
AR
Argentina
Prior art keywords
cr8r8
alkyl
alkenyl
aryl
heterocyclic
Prior art date
Application number
ARP020100149A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR032398A1 publication Critical patent/AR032398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Un compuesto de escuaramida de sulfonamida de la formula (1) en la que R1 se selecciona independientemente entre el grupo que consta de hidrogeno, halogeno, nitro, ciano, alquilo de C1-10 sustituido con halogeno, alquilo de C1-10, alquenilo de C2-10, alcoxi C1-10, alcoxi de C1-10 sustituido con halogeno, azida, (CR8R8)qS(O)tR4, hidroxi, hidroxialquilo de C1-4, arilo, aril-alquilo de C1-4, ariloxi, aril-alquil(C1-4)oxi, heteroarilo, heteroarilalquilo, heterocíclico, heterocíclico-alquilo de C1-4, heteroaril-alquil(C1-4)oxi, arilalquenilo de C2-10, heteroaril-alquenilo de C2-10) heterocíclico-alquenilo de C2-10, (CR8R8)qN-R4R5, alquenilo(C2-10)C(O)NR4R5, (CR8R8)qC(O)-NR4R5, (CR8R8)q-C(O)NR4R10, S(O)3H, S(O)3R8, (CR8R8)qC(O)R11, alquenil-(C2-10)C(O)R11, alquenil(C2-10)C(O)OR11(CR8R8)q-C(O)OR12, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)q-NHS(O)2R17, (CR8R8)q y S(O)2NR4R5; o dos restos R1 juntos forman O-(CH2)sO- o un anillo insaturado de 5 a 6 miembros; Rb se selecciona independientemente entre el grupo que consta de hidrogeno, NR6R7, OH, ORa, alquilo de C1-5, arilo, aril-alquilo de C1-4, aril-alquenilo de C2-4, cicloalquilo, cicloalquil-alquilo de C1-5 heteroarilo, heteroaril-alquilo de C1-4, heteroaril-alquenilo de C2-4, heterocíciclo, heterocíclico-alquilo de C1-4, y un resto heterocíclico-alquenilo de C2-4; todos cuyos restos pueden estar sustituidos opcionalmente uno a tres veces, independientemente, con halogeno, nitro, alquilo, de C1-4 sustituido con halogeno, alquilo de C1-4; amino, amina mono o disustituida con alquilo de C1-4, ORa, C(O)Ra, NRaC(O)ORa, OC(O)NR6R7, hidroxi, NR9C(O)Ra, S(O)m'Ra, C(O)NR6R7, C(O)OH, C(O)Ora, S(O)2NR6R7 y NHS(O)2Ra; o los dos sustituyentes Rb pueden unirse para formar un anillo de 3-10 miembros, opcionalmente sustituido y que contiene además de carbono, independientemente, 1 a 3 restos NRa, O, S, SO o SO2 que pueden estar, opcionalmente insaturados; en donde q, t, s, R4 y R5 son como se definen en la memoria; Y se selecciona independientemente entre el grupo que consta de hidrogeno, halogeno, nitro, ciano, alquilo de C1-10 sustituido con halogeno, alquilo C1-10, alquenilo de C2-10, alcoxi de C1-10, alcoxi de C1-10 sustituido con halogeno, azida, (CR8R8)qS(O)tR4, Hidroxi, hidroxialquilo de C1-4, arilo, aril-alquilo de C1-4, ariloxi, aril-alquil(C1-4)oxi, heteroarilo, heteroarilalquilo, hetero-aril-alquil(C1-4)oxi, heterocíclico, heterocíclico-alquilo de C1-4; aril-alquenilo de C2-10, heteoaril-alquenilo de C2-10, heterocíclico-alquenilo de C2-10, (CR8R8)qNR4R5, alquenil(C2-10)C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3H, S(O)3R8, (CR8R8)qC(O)R11, alquenil(C2-10)C(O)R11, alquenil(C2-10)C(O)OR11, C(O)R11, (CR8R8)qC(O)OR12, (CR8R8)qOC(O)R11, (CR8R8)qNR4-C(O)R11, (CR8R8)qNHS(O)2Rd, y (CR8R8)qS(O)2NR4R5, o dos restos Y juntos forman O-(CH2)sO- o un anillo insaturado de 5 a 6 miembros; n es un numero entero que tiene un valor de 1 a 5; m es un numero entero que tiene un valor de 1 a 4; y en donde R8, R10, R11, R12, R17 son como se definen en la memoria. Una composicion farmacéutica que comprende una cantidad eficaz de un compuesto de la formula (1), y un excipiente o diluyente farmacéuticamente aceptable. Uso de un compuesto de la formula (1) para preparar una composicion farmacéutica de aplicacion de un método de tratamiento de un estado de enfermedad en un mamífero que cursa con mediacion de una quimioquina, en el que la quimioquina se une a un receptor de IL-8alfa o beta, dicho método comprende administrar a dicho mamífero una cantidad eficaz de dicho compuesto.
ARP020100149A 2001-01-16 2002-01-16 Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion AR032398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26190601P 2001-01-16 2001-01-16

Publications (1)

Publication Number Publication Date
AR032398A1 true AR032398A1 (es) 2003-11-05

Family

ID=22995388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100149A AR032398A1 (es) 2001-01-16 2002-01-16 Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion

Country Status (8)

Country Link
US (2) US20040048897A1 (es)
EP (1) EP1351933B1 (es)
JP (1) JP2004521106A (es)
AR (1) AR032398A1 (es)
AT (1) ATE346043T1 (es)
DE (1) DE60216229T2 (es)
ES (1) ES2276926T3 (es)
WO (1) WO2002057230A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1818325E (pt) * 2001-04-16 2010-05-12 Schering Corp Ciclobuteno-1,2-dionas 3,4-di-substituídas como ligandos de receptor de quimoquina cxc
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003031440A1 (en) 2001-10-12 2003-04-17 Schering Corporation 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
NZ535314A (en) 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
AU2003288922A1 (en) 2002-10-09 2004-05-04 Pharmacopeia, Inc. Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
MY143477A (en) * 2002-10-29 2011-05-31 Smithkline Beecham Corp Il-8 receptor antagonists
ES2308299T3 (es) 2003-12-19 2008-12-01 Schering Corp Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
WO2005068460A1 (en) 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
US7059517B2 (en) * 2003-12-31 2006-06-13 Hewlett-Packard Development Company, L.P. On-line PIN verification using polynomials
JP2008517054A (ja) * 2004-10-20 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
WO2007002764A2 (en) 2005-06-29 2007-01-04 Schering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands
ATE486078T1 (de) 2005-06-29 2010-11-15 Schering Corp 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors
JP2009534420A (ja) * 2006-04-21 2009-09-24 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US7893089B2 (en) * 2006-04-21 2011-02-22 GlaxoSmithKline, LLC IL-8 receptor antagonists
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
EP2155670B1 (en) 2007-06-06 2012-04-18 Novartis AG Anti -inflammatory substituted cyclobutenedione compounds
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) * 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
PL2760821T3 (pl) 2011-09-02 2018-04-30 Novartis Ag Sól cholinowa przeciwzapalnego związku podstawionego cyklobutenodionem
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
AU2018318075B2 (en) 2017-08-14 2023-04-13 Allergan, Inc. 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
WO2019136370A2 (en) 2018-01-08 2019-07-11 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
CN111362871B (zh) * 2018-12-25 2022-05-17 北京福元医药股份有限公司 取代的吡啶-2-甲酰胺类化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
US7008962B2 (en) * 2000-05-30 2006-03-07 Smithkline Beecham Corporation IL-8 receptor antagonists

Also Published As

Publication number Publication date
EP1351933A1 (en) 2003-10-15
EP1351933A4 (en) 2005-09-07
EP1351933B1 (en) 2006-11-22
ES2276926T3 (es) 2007-07-01
ATE346043T1 (de) 2006-12-15
JP2004521106A (ja) 2004-07-15
US20040048897A1 (en) 2004-03-11
DE60216229D1 (de) 2007-01-04
US20060084641A1 (en) 2006-04-20
DE60216229T2 (de) 2007-10-04
WO2002057230A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AR032398A1 (es) Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion
CO4990929A1 (es) Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8
CO5280059A1 (es) Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones
AR033803A1 (es) Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
AR015425A1 (es) Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
CO5261605A1 (es) Compustos farmaceuticos
CO5310550A1 (es) Nuevo derivado de androstano antiinflamatorio, su polimorfo, sus formas cristalinas solvatadas, composiciones farmaceutias, proceso para prepararlo, intermediario
CO4890843A1 (es) Antagonistas de los receptores de il-8 de il-8
AR011101A1 (es) Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene
AR011189A1 (es) 1,4-benzotiazepin-1,1-dioxidos hipolipemiantes, composiciones farmaceuticas, uso de dichos compuestos para fabricar medicamentos y metodos para preparar dichos compuestos y compuestos intermediarios para su preparacion
AR023681A1 (es) Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento.
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
BRPI0606455A (pt) compostos farmacêuticos
DK1200390T3 (da) Fremstilling af N-substituerede 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamider
CL2004001109A1 (es) Compuestos tien-3-il-sulfonilamino(tio) carbonil-triazolin(tio)onas sustituidas; procedimiento de obtencion; compuestos intermediarios; uso de los compuestos; y agentes herbicidas.
CO5601012A2 (es) Compuestos que modulan la actividad de ppar
AR021354A1 (es) Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica
AR064521A1 (es) Activador de glucoquinasa
ECSP003792A (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
CO5031286A1 (es) Compuestos de ciano guanadina como antagonistas de los receptores de il-8 y metodo de preparacion
AR008331A1 (es) Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure